

### REMARKS

In the Office Action mailed October 11, 2007, Claims 22-31 are pending in the application. Claims 22-41 are subject to restriction and/or election requirement. Claims 22-37 and 39-41 are withdrawn. Claim 38 has been amended. Claims 42-56 have been added. Claims 38 and 42-56 remain.

In response to the above-noted Office Action, Applicant has elected Group VI, corresponding to a depigmenting method using an oligonucleotide comprising SEQ ID NO: 1, with traverse.

Applicant further notes that contrary to the restriction between product and method claims, the restriction required by the Examiner concerns the selection of a particular sequence comprised by the oligonucleotide specific for PKC beta-1. In this regard, Applicant submits that this restriction requirement is not proper, since all sequences have in common being specific for PKC beta-1.

In view of the foregoing amendment and response, Applicant submits that the claims pending for examination, namely claims 38 and 42-56 are now in condition for allowance, which early action is requested.

If there are any fees due in connection with the filing of this response, please charge those fees to our Deposit Account No. 02-2666. If a telephone interview would expedite the prosecution of this Application, the Examiner is invited to contact the undersigned at (310) 207-3800.

### PETITION FOR EXTENSION OF TIME

Per 37 C.F.R. 1.136(a) and in connection with the Office Action mailed on October 11,

### REMARKS

In the Office Action mailed October 11, 2007, Claims 22-31 are pending in the application. Claims 22-41 are subject to restriction and/or election requirement. Claims 22-37 and 39-41 are withdrawn. Claim 38 has been amended. Claims 42-56 have been added. Claims 38 and 42-56 remain.

In response to the above-noted Office Action, Applicant has elected Group VI, corresponding to a depigmenting method using an oligonucleotide comprising SEQ ID NO: 1, with traverse.

Applicant further notes that contrary to the restriction between product and method claims, the restriction required by the Examiner concerns the selection of a particular sequence comprised by the oligonucleotide specific for PKC beta-1. In this regard, Applicant submits that this restriction requirement is not proper, since all sequences have in common being specific for PKC beta-1.

In view of the foregoing amendment and response, Applicant submits that the claims pending for examination, namely claims 38 and 42-56 are now in condition for allowance, which early action is requested.

If there are any fees due in connection with the filing of this response, please charge those fees to our Deposit Account No. 02-2666. If a telephone interview would expedite the prosecution of this Application, the Examiner is invited to contact the undersigned at (310) 207-3800.

### PETITION FOR EXTENSION OF TIME

Per 37 C.F.R. 1.136(a) and in connection with the Office Action mailed on October 11,

2007, Applicant respectfully petitions Commissioner for a one (1) month extension of time, extending the period for response to December 11, 2007. The Commissioner is authorized to charge Deposit Account No. 02-2666 in the amount of \$120 to cover the petition filing fee for a 37 C.F.R. 1.17(a)(1) large entity.

Respectfully submitted,

BLAKELY, SOKOLOFF, TAYLOR, & ZAFMAN

Dated: 12/11/07

By:   
Eric S. Hyman, Reg. No. 30,139

1279 Oakmead Parkway  
Sunnyvale, CA 94085-4040  
Telephone: (310) 207-3800  
Facsimile: (408) 720-8383

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

  
Suzanne Johnston

12/11/07  
Date